Literature DB >> 19235658

Candidate selection and organ allocation in liver transplantation.

Muhammad F Dawwas1, Alexander E Gimson.   

Abstract

Optimal candidate selection and organ allocation should offer liver transplantation to those who are sufficiently sick to justify the procedure but not too sick to benefit from it, in an order determined by patients' projected survival benefit, matching organs of sufficiently good quality to the appropriate recipients. Significant steps have been made in recent years toward devising selection and allocation criteria based on more objective and evidence-based definitions of candidate disease severity, transplant futility, organ quality, and appropriate donor-recipient matching. However, much work remains to be done in the future.

Entities:  

Mesh:

Year:  2009        PMID: 19235658     DOI: 10.1055/s-0029-1192054

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  10 in total

1.  Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus.

Authors:  Fotios Sampaziotis; William J H Griffiths
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

2.  D-MELD risk capping improves post-transplant and overall mortality under markov microsimulation.

Authors:  Jeffrey B Halldorson; Robert L Carithers; Renuka Bhattacharya; Ramasamy Bakthavatsalam; Iris W Liou; Andre A Dick; Jorge D Reyes; James D Perkins
Journal:  World J Transplant       Date:  2014-09-24

3.  Liver Living Donation for Cancer Patients: Benefits, Risks, Justification.

Authors:  Silvio Nadalin; Lara Genedy; Alfred Königsrainer
Journal:  Recent Results Cancer Res       Date:  2021

Review 4.  Overview of the indications and contraindications for liver transplantation.

Authors:  Stefan Farkas; Christina Hackl; Hans Jürgen Schlitt
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

Review 5.  Organ allocation for chronic liver disease: model for end-stage liver disease and beyond.

Authors:  Sumeet K Asrani; W Ray Kim
Journal:  Curr Opin Gastroenterol       Date:  2010-05       Impact factor: 3.287

6.  Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.

Authors:  Sanjeeva P Kalva; Shams I Iqbal; Kalpana Yeddula; Lawrence S Blaszkowsky; Adnan Akbar; Stephan Wicky; Andrew X Zhu
Journal:  Gastrointest Cancer Res       Date:  2011-01

7.  Living donor liver transplantation for high model for end-stage liver disease score: What have we learned?

Authors:  Hany Dabbous; Mohammad Sakr; Sara Abdelhakam; Iman Montasser; Mohamed Bahaa; Hany Said; Mahmoud El-Meteini
Journal:  World J Hepatol       Date:  2016-08-08

Review 8.  Management of acute liver failure.

Authors:  R Todd Stravitz; David J Kramer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-04       Impact factor: 46.802

9.  Moving toward the utilization of all donated liver grafts. The "b-list" concept.

Authors:  D Vrochides; P Metrakos
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

10.  Pretransplant prediction of posttransplant survival for liver recipients with benign end-stage liver diseases: a nonlinear model.

Authors:  Ming Zhang; Fei Yin; Bo Chen; You Ping Li; Lu Nan Yan; Tian Fu Wen; Bo Li
Journal:  PLoS One       Date:  2012-03-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.